Frontiers of Biomedical Science

On October 19-20, 2005 eminent scientists from Europe, the US and China met to explore the most critical issues and research on the forefront of four cutting-edge disciplines:

• Chemical Biology
• Infectious Disease
• Genomic Medicine
• Neuroscience

Plenary lectures were combined with four concurrent interactive workshops attended by elite young Chinese scientists and international representatives from academia and industry.

Speakers

• Soren F. Andersen (Wyeth Research)
• Emile-Etienne Baulieu (Cedex)
• Jan Carlstedt-Duke (Karolinska Institute)
• Zhu Chen (Chinese Academy of Sciences)
• Virginia Cornish (Columbia University)
• Peter B. Corr (Pfizer, Inc.)
• Lin He (Shanghai Jiao-Tong University)
• Hua-Liang Jiang (Shanghai Institute of Materia Medica, CAS)
• Keith Jones (Affymetrix, Inc.)
• Xiang-Yun Kong (Health Science Center, SIBS, CAS)
• Bruce Lahn (Howard Hughes Medical Institute)
• Chi-Ming Lee (AstraZeneca Pharmaceuticals LP)
• Marc Lipsitch (Harvard School of Public Health)
• Da-Wei Ma (Shanghai Institute of Organic Chemistry, CAS)
• Jeremy Paul (New York Academy of Sciences)
• David Perlin (Public Health Research Institute)
• John Reid (AstraZeneca Pharmaceuticals LP)
• Glenn Rice (Bridge Pharmaceuticals, Inc.)
• Ellis Rubinstein (New York Academy of Sciences)
• Joanna Rubinstein (Columbia University Medical School)
• Bin Sun (Institute of Biochemistry and Cell Biology, SIBS, CAS)
• Gregory Verdine (Harvard University)
• Yi-Zheng Wang (Institute of Neuroscience, SIBS, CAS)
• Jiarui Wu (Shanghai Institutes for Biological Science, CA)
• Zheng-Hong Yuan (Fu-Dan University)
• Xu Zhang (Institute of Neuroscience, SIBS, CA)

The meeting has been made possible with funding from

• Alexandria Real Estate Equities
• AstraZeneca
• Pfizer
• Affymetrix
• Wyeth
• Lundbeck
• Bridge Pharmaceuticals
• CMEA Ventures
• Nature Publishing Group
• The Karolinska Institute
• PricewaterhouseCoopers.